Lactobacillus Plantarum: Double Blind Placebo Effect for Depression Treatment

Probiotic composition for self-treatment of mental exhaustion conditions. The composition contains specific strains of lactobacilli, bifidobacteria, and lactococcus bacteria. It aims to address the submerged part of the symptom iceberg, where self-reported symptoms like mental exhaustion are not typically brought to medical attention. The composition is for self-medication to improve mental resilience and reduce mental exhaustion by modulating serotonin levels. It contains strains like Lactobacillus casei W56, Bifidobacterium lactis W51, and Lactococcus lactis W19.

Source

A psychobiotic composition comprising a mixture of bacterial strains, including Levilactobacillus brevis, Lactiplantibacillus plantarum, and Bifidobacterium bifidum, for the prevention and/or treatment of neurodegenerative diseases, mental illnesses, and psychiatric disorders. The composition is administered orally and has been shown to reduce disease symptoms and biomarkers in animal models of Parkinson's disease and other neurodegenerative conditions.

Source

A probiotic product for improving mood, comprising Lactobacillus plantarum JYLP-326, which regulates intestinal inflammation and modulates the gut-brain axis to alleviate symptoms of depression. The product enhances intestinal barrier integrity, reduces pro-inflammatory cytokines, and inhibits the RAGE-TLR4 signaling pathway in the hippocampus. It also restores balanced gut microbiota by increasing Lactobacillus abundance and reducing Sutterella and Eubacterium muciniphilum populations.

Source

Lactobacillus gasseri strain BDUP with high GABA production for use in foods, supplements, and medications to provide natural GABA for stress relief, improving sleep, and treating depression. The strain can be used to produce GABA through fermentation or extract GABA metabolites. It also has potential as a probiotic to alleviate depressive-like behavior in mice.

Source

Compositions and methods for treating mental health disorders and other conditions associated with low levels of gamma-aminobutyric acid (GABA) using a probiotic bacterium that produces GABA. The bacterium, such as Bifidobacterium adolescentis or Lactiplantibacillus plantarum, is administered in a therapeutically effective amount to a subject in need of treatment. The GABA-producing bacterium acts on the brain-gut axis to alleviate symptoms of mental health disorders, including anxiety, depression, and epilepsy, as well as other conditions such as chronic pain, fatigue, and inflammation.

Source

Compositions comprising a probiotic lactic acid bacteria and a milk fat globule membrane for promoting neurotransmitter production in the gut, particularly serotonin, to alleviate symptoms of depression, anxiety, and stress. The compositions can be formulated into food products, such as a calming dark chocolate pudding with a white chocolate topping containing live cultures, for convenient consumption.

Source

Abstract This study examined the efficacy of a probiotic in reducing depressive symptom severity in people with subthreshold depression. In a double-blind, randomised, placebo-controlled trial, a probiotic (1 10^9 live cells per strain: Limosilactobacillus fermentum LF16 (DSM26956), Lacticaseibacillus rhamnosus LR06 (DSM21981), Lactiplantibacillus plantarum LP01 (LMG P-21021) and Bifidobacterium longum 04 (DSM23233)) or placebo was taken daily for 12 weeks. Data were collected at baseline, 6 and 12 weeks including psychological symptom severity (Beck Depression Inventory, BDI; Patient Health Questionnaire, PHQ; Hospital Anxiety Depression Scale, HADS; and Depression Anxiety and Stress Scale, DASS). Biomarkers of glycaemia, inflammation (high-sensitivity C-reactive protein, hs-CRP), antioxidant status (total glutathione (GSH)) and stress (cortisol awakening response, CAR) were also measured. Thirty-nine participants (nineteen probiotic; twenty placebo) were enrolled. There were no significant between-group differences in the examined psychological symptom severity scores, despite ce... Read More

Source

A lactobacillus strain specifically engineered for gut microbiota modulation in psychiatric disorders. The strain, designated as Lactobacillus 1, has been isolated from human gut microbiota and demonstrated superior survival and biochemical activity in simulated gastric and intestinal environments, indicating its potential therapeutic applications in psychiatric conditions.

Source

A multi-strain probiotic formulation comprising Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve, and Bifidobacterium infantis, administered in combination with glutamine, for treating treatment-resistant depression (TRD) by modulating the gut-brain axis and restoring balance to the gut microbiome.

Source

Major depressive disorder is a condition involving microbiota-gut-brain axis dysfunction. Increasing research aims to improve depression through gut microbiota regulation, including interventions such as probiotics, prebiotics, and fecal microbiota transplants. However, most research focuses on exogenous depression induced by chronic stress or drugs, with less attention given to endogenous depression. Additionally, research on gut mycobiota in depression is significantly less than that on gut bacteria.

Source

Following on from our pilot studies, this study aimed to test the efficacy of a combination of probiotics (Lactobacillus acidophilus, Bifidobacterium bifidum, Streptococcus thermophilus), magnesium orotate and coenzyme 10 for the treatment of major depressive disorder (MDD) through a double-blind placebo controlled clinical trial. The participants were 120 adults diagnosed with MDD randomised to daily oral administration, over 8 weeks, of either the intervention or placebo, with a 16-week follow-up period. Intent-to-treat analysis found a significantly lower frequency of the presence of a major depressive episode in the intervention group compared with placebo at the end of the 8-week treatment phase, with no difference between the two conditions at 8-week follow-up. Both the categorical and continuous measure of depressive symptoms showed a significant difference between the two conditions at 4 weeks, but not 8 and 16 weeks. The secondary end-point was demonstrated with an overall reduction in self-rated symptoms of anxiety and stress in the active treatment group compared with plac... Read More

Source

Modifying the gut microbiome to treat mental health disorders by administering a combination of beneficial bacteria species, such as Lacticaseibacillus paracasei, Coprococcus, and Faecalibacterium prausnitzii, to regulate mood, reduce anxiety and depression, and promote brain health. The treatment aims to restore balance to the gut-brain axis by enhancing the production of short-chain fatty acids, such as butyrate, and reducing inflammation.

Source

Using specific strains of bacteria, like Bifidobacterium bifidum, Bifidobacterium longum, and Lactobacillus paracasei, to improve mood disorders and cognitive function. The bacteria strains can be used in supplements for treating brain disorders like anxiety, depression, and dementia. The strains can also be used to improve cognitive function and prevent cognitive decline. The supplements can contain the strains alone or in combinations. The bacteria strains may be lyophilized for convenient dosing.

Source

Probiotics may represent a safe and easy-to-use treatment option for depression or its metabolic comorbidities. However, it is not known whether metabolic features can influence the efficacy of probiotics treatments for depression. This trial involved a parallel-group, prospective, randomized, double-blind, controlled design. In total, 116 participants with depression received a probiotic preparation containing Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 or placebo over 60 days. The psychometric data were assessed longitudinally at five time-points. Data for blood pressure, body weight, waist circumference, complete blood count, serum levels of C-reactive protein, cholesterol, triglycerides, and fasting glucose were measured at the beginning of the intervention period. There was no advantage of probiotics usage over placebo in the depression score overall (PRO vs. PLC: F(1.92) = 0.58; p = 0.45). However, we found a higher rate of minimum clinically important differences in patients supplemented with probiotics than those allocated to placebo generally (... Read More

Source

Probiotic compositions for preventing and treating stress-related conditions like impaired cognitive function, anxiety, insomnia, baby blues, postpartum depression, menopausal depression, generalized anxiety disorder, major depressive disorder, panic attacks, attention deficit disorder. The compositions contain a combination of probiotic strains, Lactobacillus reuteri PBS072 and Bifidobacterium breve BB077 or Bifidobacterium lactis BL050.

Source

As an essential counterpart of the human internal environment, the gut microbiome has been investigated extensively in light of multiple diseases. This study aims to find out potential treatments for depression by altering gut microbiome composition in order to alleviate side effects caused by traditional medications. According to previous findings, the human gut correlates with the brain through pathways known as the gut-brain axis. Two genera of microbiome, Lactobacillus and Bifidobacterium, have been mentioned by researchers to be crucial to depression-related neurotransmitter secretion in GBA. Besides, they have already been used in clinical as effective probiotics for gut-related diseases. The paper hypothesized particular interactions between the two genera and the human nerve that enable them to be therapeutic cures in adequate amounts. In this study, a range of available single-cell data about depression and lactobacillus and bifidobacterium were analyzed and adjusted into proper figures. I discuss the efficacy of different species, concentrations, and other elements of those... Read More

Source

Abstract Background According to the Institute of Health Metrics and Evaluations Global Health Data Exchange (2023) it is estimated that 5% of all adults will experience depressive disorder. Amongst the general loss of pleasure and interest in everyday activities that are symptoms of low mood, reduced sexual desire and sexual dysfunction can be particularly overlooked. Human sexuality is complex, but finding solutions based on scientific evidence to limit the symptoms of depressive disorder and the iatrogenic impact of antidepressant treatment to improve this outcome is an important step in promoting psychological health and general wellbeing. Objective The present study aimed is to provide scientific evidence to assess the effect of oral probiotic on sexual function in women with depressive disorder treated with Selective Serotonin Reuptake Inhibitors (SSRIs) in an Iranian population. Design This study was a double-blind randomized clinical trial. Eligible women were assigned to lactofem plus SSRIs ( n = 58) or SSRIs alone ( n = 54). In group A, SSRI antidepressants were prescribed... Read More

Source

Synbiotic composition containing specific bacterial strains and dietary fibers for treating neuropsychiatric disorders, reducing disorder symptoms, and mitigating side effects of pharmacological treatments. The synbiotic comprises Lactobacillus plantarum, Lactobacillus paracasei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Bifidobacterium breve bacteria strains along with inulin, pectin, beta-glucan, resistant starch, galacto-oligosaccharide, isomalto-oligosaccharide, or rice fiber. Administering this synbiotic composition improves neuropsychiatric disorder conditions like ADHD, reduces inflammation markers, and enhances short chain fatty acid production in the gut.

Source

Major depressive disorder (MDD) is a complex mental disorder, potentially linked to the gut-microbiota-brain axis. Probiotics like Lactobacillus plantarum PS128 (PS128) may improve depressive symptoms by modulating the gut microbiota based on our previous open trial. We conducted an 8-week double-blind, placebo-controlled trial to investigate the impact of PS128 on depression severity, markers of inflammation and gut permeability, and the gut microbiota composition in 32 patients with MDD with stable antidepressant treatment but moderate symptom severity. Following the 8-week intervention, both the Hamilton Depression Rating Scale-17 score (HAMD), and Depression and Somatic Symptoms Scale (DSSS) showed a significant decrease in both groups (p<0.001). However, there was no significant difference in the change of depression severity between groups (p=0.203). Moreover, alterations in serum levels of high sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-, and intestinal fatty acid binding protein, as well as changes in the gut microbiota composition, did not exhibit ... Read More

Source

Depression is the leading cause of disability worldwide (1) . The microbiota-gut-brain axis may play a role in the aetiology of depression, and probiotics show promise for improving mood and depressive state (2) . Further evidence is required to support mechanisms and in high-risk populations, such as those with sub-threshold depression (which may be 2-3 times more prevalent than diagnosed depression) (3) . The aims were to assess the efficacy of a probiotic compared with placebo in reducing the severity of depressive symptoms in participants with subthreshold depression, and to investigate potential mechanistic markers of inflammatory, antioxidant status and stress response. A double-blind, randomised, placebo-controlled trial was conducted in participants meeting diagnosis of subthreshold depression (DSM-5); aged 18-65 years; 18.5 kg/m 2 body mass index; not taking antidepressants, centrally acting medications, probiotics nor antibiotics for at least 6 weeks. The probiotic (4 10 9 AFU/CFU, 2.5 g freeze-dried powder containing Lactobacillus fermentum LF16 (DSM26956), L. rhamnosus... Read More

Source